RT Journal Article
SR Electronic
T1 Neutralization breadth of SARS CoV-2 viral variants following primary series and booster SARS CoV-2 vaccines in patients with cancer
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.11.10.21265988
DO 10.1101/2021.11.10.21265988
A1 Vivek Naranbhai
A1 Kerri J St. Denis
A1 Evan C Lam
A1 Onosereme Ofoman
A1 Wilfredo-Garcia Beltran
A1 Cristhian Berrios
A1 Atul K. Bhan
A1 Justin F. Gainor
A1 Alejandro B. Balazs
A1 A. John Iafrate
A1 on behalf of the CANVAX team
YR 2021
UL http://medrxiv.org/content/early/2021/11/11/2021.11.10.21265988.abstract
AB Patients with cancer are more likely to have impaired immune responses to SARS CoV-2 vaccines. We studied the breadth of responses against SARS CoV-2 variants followingly primary vaccination in 178 patients with a variety of tumor types, and after booster doses in a subset. Neutralization of alpha, beta, gamma and delta SARS-CoV-2 variants was impaired relative to wildtype (Wuhan), regardless of vaccine type. Regardless of viral variant, mRNA1273 was the most immunogenic, followed by BNT162b2 and then Ad26.COV2.S. Neutralization of more variants (breadth) was associated with higher magnitude of wildtype neutralization, and increase with time since vaccination; increased age associated with lower breadth. Anti-spike binding antibody concentrations were a good surrogate for breadth (PPV=90% at >1000U/ml). Booster SARS-CoV-2 vaccines conferred enhanced breadth. These data suggest that achieving a high antibody titer is desirable to achieve broad neutralization; a single booster dose with current vaccines increases breadth of responses against variants.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by the Charles H. Hood Foundation, Lambertus Family Foundation, Donald Glazer, National Institutes for Drug Abuse (NIDA) Avenir New Innovator Award DP2DA040254 and the MGH Transformative Scholars Program.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:IRB of Massachusetts General Hospital gave ethical approval for this workI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors